New cancer clinical trial: Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer

Published on: August 27, 2018 at 12:00PM
Condition:   Colorectal Cancer Metastatic
Interventions:   Drug: Nivolumab 10 MG/ML;   Drug: BNC 105;   Drug: BBI608
Sponsor:   Australasian Gastro-Intestinal Trials Group
Not yet recruiting
https://ift.tt/2NsPVtb